Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.

Saved in:
Bibliographic Details
Title: Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study.
Authors: Naranbhai V; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA.; Dana-Farber Cancer Institute, Boston, MA.; Center for the AIDS Programme of Research in South Africa, Durban, South Africa., Pernat CA; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Gavralidis A; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA.; Salem Hospital, Salem, MA., St Denis KJ; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA., Lam EC; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA., Spring LM; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Isakoff SJ; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Farmer JR; Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Zubiri L; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Hobbs GS; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., How J; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA., Brunner AM; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Fathi AT; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Peterson JL; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Sakhi M; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Hambelton G; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Denault EN; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Mortensen LJ; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Perriello LA; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Bruno MN; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Bertaux BY; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Lawless AR; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Jackson MA; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Niehoff E; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Barabell C; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Nambu CN; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Nakajima E; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Reinicke T; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Bowes C; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA., Berrios-Mairena CJ; Department of Pathology, Massachusetts General Hospital, Boston, MA., Ofoman O; Department of Pathology, Massachusetts General Hospital, Boston, MA., Kirkpatrick GE; Department of Pathology, Massachusetts General Hospital, Boston, MA., Thierauf JC; Department of Pathology, Massachusetts General Hospital, Boston, MA., Reynolds K; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Willers H; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA., Beltran WG; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA.; Department of Pathology, Massachusetts General Hospital, Boston, MA., Dighe AS; Department of Pathology, Massachusetts General Hospital, Boston, MA., Saff R; Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Blumenthal K; Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Sullivan RJ; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Chen YB; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Kim A; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA., Bardia A; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA., Balazs AB; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA., Iafrate AJ; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA.; Department of Pathology, Massachusetts General Hospital, Boston, MA., Gainor JF; Massachusetts General Hospital Cancer Center, Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Jan 01; Vol. 40 (1), pp. 12-23. Date of Electronic Publication: 2021 Nov 09.
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO.21.01891